EUVIMEDEUVIMED entdecken
Fallbericht

Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet

Motokazu Sato, Qinghong Han, Ryosuke Mori, Kohei Mizuta, Byung Mo Kang, Sei Morinaga, Noritoshi Kobayashi, Yasushi Ichikawa, Atsushi Nakajima, Robert M Hoffman

Anticancer Research · 2024

DOI: 10.21873/anticanres.16946 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Anticancer Research, 2024. Verfasst von Motokazu Sato und 9 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc., San Diego, CA, U.S.A. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Carbon-Sulfur Lyases. Die Arbeit wurde bisher 11-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesCarbon-Sulfur LyasesHumansFemaleAgedBiomarkers, TumorTrastuzumabMethionineRacemethionineDietErb-b2 Receptor Tyrosine KinasesCamptothecin

Stichwörter der Autor:innen

Breast cancerEnhertuHER2-positiveHoffman effectcombination therapyirinotecanmethionine addictionmethionine restrictionoral methioninasesynergytrastuzumab deruxtecan

Substanzen

Biomarkers, TumorTrastuzumabImmunoconjugatesMethionineRacemethionineErb-b2 Receptor Tyrosine KinasesCamptothecinCarbon-Sulfur Lyasestrastuzumab deruxtecanL-methionine gamma-lyase

Autor:innen und Institutionen

  • AntiCancer Inc., San Diego, CA, U.S.A.
  • Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Department of Oncology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
  • AntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Zitieren

APA

Sato, M., Han, Q., Mori, R., Mizuta, K., Kang, B. M., Morinaga, S., Kobayashi, N., Ichikawa, Y., Nakajima, A., & Hoffman, R. M. (2024). Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet. Anticancer Research. https://doi.org/10.21873/anticanres.16946

Vancouver

Sato M, Han Q, Mori R, Mizuta K, Kang BM, Morinaga S, et al. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet. Anticancer Research. 2024. doi:10.21873/anticanres.16946

BibTeX
@article{Sato2024,
  author = {Sato, Motokazu and Han, Qinghong and Mori, Ryosuke and Mizuta, Kohei and Kang, Byung Mo and Morinaga, Sei and Kobayashi, Noritoshi and Ichikawa, Yasushi and Nakajima, Atsushi and Hoffman, Robert M},
  title = {Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16946}
}
Kostenlos starten →